Long-term clinical results and predictors of adverse outcomes after drug-eluting stent implantation for bifurcation lesions in a real-world practice: the COBIS (Coronary Bifurcation Stenting) registry.

BACKGROUND Limited data exists regarding long-term clinical results and predictors of adverse outcomes after drug-eluting stents (DES) implantation for coronary bifurcation lesions in a real-world practice. METHODS AND RESULTS A total of 1,691 non-left main bifurcation lesions with side branches ≥2.0mm in 1,668 patients undergoing DES implantation between January 2004 and June 2006 from 16 centers in Korea were evaluated. True bifurcation was found in 69.2% of lesions and 82.7% of lesions were treated with 1-stent technique. During follow-up (median 22 months), cardiac death occurred in 0.9%, myocardial infarction (MI) in 1.2%, target lesion revascularization (TLR) in 4.7% and stent thrombosis in 0.7% of patients. There was no significant difference in major adverse cardiac events (MACE: composite of cardiac death, MI and TLR) between the 1-stent and the 2-stent groups (6.1% vs 7.5%, P=0.36). Stent length in the main vessel (hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.001-1.03, P=0.03), paclitaxel-eluting stent (HR 1.98, 95%CI 1.34-2.92, P=0.001) and kissing ballooning (HR 2.01, 95%CI 1.29-3.13, P=0.002) were independent predictors of MACE. Kissing ballooning increased the risk of MACE especially in the 1-stent group, but not in the 2-stent group. CONCLUSIONS In this large real-world registry, overall outcomes after DES implantation in bifurcation lesions were favorable and similar between the 1-stent and 2-stent groups.

[1]  Antonio Colombo,et al.  Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study , 2009, Circulation.

[2]  Y. Honda Drug-eluting stents. Insights from invasive imaging technologies. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[3]  Young‐Bae Park,et al.  Physiologic assessment of jailed side branch lesions using fractional flow reserve. , 2005, Journal of the American College of Cardiology.

[4]  M. Pan,et al.  Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. , 2004, American heart journal.

[5]  J. Ivanov,et al.  Long-term outcomes after percutaneous coronary intervention of bifurcation narrowings. , 2008, The American journal of cardiology.

[6]  Y. Hayashi,et al.  Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.

[7]  I. Komuro,et al.  Re-restenosis and target lesion revascularization after treatment of sirolimus-eluting stent restenosis: retrospective analysis of 4 Japanese hospitals. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[8]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[9]  M. Farnier,et al.  Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. , 2007, American heart journal.

[10]  J. Ge,et al.  Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomised trials , 2009, Heart.

[11]  P. Serruys,et al.  Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. , 2006, Journal of the American College of Cardiology.

[12]  Antonio Colombo,et al.  Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions , 2004, Circulation.

[13]  Y. Honda,et al.  Drug-Eluting Stents , 2009 .

[14]  P. Serruys,et al.  Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. , 2004, The American journal of cardiology.

[15]  A. Colombo,et al.  Predictors of restenosis after treatment of bifurcational lesions with paclitaxel eluting stents: A multicenter prospective registry of 150 consecutive patients , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[16]  J. Suárez de Lezo,et al.  Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. , 2007, American heart journal.

[17]  K. Hirata,et al.  Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[18]  Young-Hak Kim,et al.  Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. , 2006, European heart journal.

[19]  I. Iakovou,et al.  Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow up of crush versus T stenting , 2005, Heart.

[20]  M. Niemelä,et al.  Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions: The Nordic Bifurcation Study , 2006, Circulation.

[21]  I. Iakovou,et al.  Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. , 2005, Journal of the American College of Cardiology.

[22]  J. Suárez de Lezo,et al.  [A new classification of coronary bifurcation lesions]. , 2006, Revista espanola de cardiologia.

[23]  Fesc,et al.  Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry , 2006, Circulation.